ValueQ4, 24TTMSelling/general/admin expenses——Research & development——Operating income——Non-Operating Income, Total——Interest expense, net of interest capitalized——Non-Operating Income, excl. Interest Expenses——Unusual income/expense——Pretax income——Equity in earnings——Taxes——Non-controlling/minority interest——After tax other income/expense——Net income before discontinued operations——Discontinued operations——Net income——Dilution adjustment——Preferred dividends——Diluted net income available to common stockholders——Basic earnings per share (Basic EPS)——Diluted earnings per share (Diluted EPS)——Average basic shares outstanding——Diluted shares outstanding——EBITDA——EBIT——Cost of revenue——Other cost of goods sold——Depreciation & amortization (cash flow)——
Cellectis S.A. - American Depositary Shares
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.